21 Oct 2026

Spain’s association of orphan and ultra-orphan medicine manufacturers has published updated access figures showing that reimbursement delays have increased during 2026. The second four-monthly report from the Spanish Association of Orphan and Ultra-Orphan Medicine Laboratories (Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos, AELMHU) covers the position at 31 August.

Of 164 orphan medicines authorised in the European Union, 141 had received a Spanish national product code and 105 were publicly funded. The funded proportion of EU-authorised medicines was therefore approximately 64%. Of those receiving funding, 62% had restrictions on indications or did not receive reimbursement across all authorised indications.

There were 36 coded orphan medicines without public reimbursement. AELMHU reports that 22 had received an explicit negative funding decision, while 14 were under assessment or had yet to enter the application process.

The association estimates an average of 34 months from assignment of the Spanish national code to inclusion in public reimbursement, compared with 23 months at the end of 2025. The measure concerns the coded-to-funded interval for the relevant cohort, not the complete period from EU marketing authorisation.

During the first eight months of 2026, the EU authorised 13 additional orphan medicines, ten received national codes in Spain and five obtained reimbursement. The figures reflect different stages of the access pathway and should not be treated as a single group of medicines.

The updated report documents both partial coverage and a lengthening measured reimbursement interval. It is industry-association evidence based on published administrative information, not an official government decision or a change to reimbursement rules.

Source: Spanish Association of Orphan and Ultra-Orphan Medicine Laboratories
Link: AELMHU publica su segundo Informe Cuatrimestral de Acceso a los Medicamentos Huérfanos 2026 (AELMHU publishes its second four-monthly 2026 orphan-medicine access report)
Date: 19 October 2026

Source: Spanish Association of Orphan and Ultra-Orphan Medicine Laboratories
Link: Informes de acceso (Access reports)
Date: 19 October 2026